A novel injectable cephalosporin, E1040, significantly eradicated Pseudomonas aeruginosa from the urine, in contrast to ceftazidime, in rats with complicated P. aeruginosa urinary tract infections associated with urinary stones, suggesting that E1040 is a prospective therapeutic agent in the management of refractory Pseudomonas urinary tract infections.
Pseudomonas aeruginosa is one of the important causative pathogens in complicated urinary tract infections. Pseudomonas complicated urinary tract infections are well known to be refractory because of resistance of the pathogen to various types of chemotherapy. For satisfactory management of Pseudomonas urinary tract infections, powerful antipseudomonal chemotherapy, as well as management of the associated causal disease, is necessary. E1040 is a novel injectable cephalosporin with a broad antibacterial spectrum that manifests especially prominent antipseudomonal activity (1, 9, 13). We therefore evaluated the efficacies of E1040 preparation used (a product of Japan Glaxo Co., Ltd.) was purchased. Both Proteus mirabilis E05106 and P. aeruginosa E030033 were isolated from a patient with a urinary tract infection. MICs and MBCs were determined by the broth microdilution method (2) . Bladder stones were induced in rats by the method of Satoh et al. (7) . Namely, a sterile zinc ring (4 mm in diameter) was surgically implanted into the bladder. At 7 days after surgery, the first test bacterium, P. mirabilis E05106 (107 CFU per rat), was inoculated transurethrally and then the second test bacterium, P. aeruginosa E030033 (108 CFU per rat), was inocu- lated in the same manner 5 days after the first inoculation.
Three types of experiments were performed as follows. In experiment 1 (short-term regimen evaluation), both E1040 and CAZ were administered intramuscularly twice a day at 20 mg/kg for 5 days beginning on day 4 after infection with P. aeruginosa. Rats were killed 24 h after the final dose. In experiment 2 (long-term regimen evaluation), both antibiotics were administered for 14 days in the manner described for experiment 1 and rats were killed 24 h after the final dose. In experiment 3 (recurrence evaluation after the long-term regimen), both antibiotics were administered for 14 days in the manner described for experiment 1 and then rats were Values connected by brackets differ significantly by the x2 test. *, P < 0.05; t, P < 0.01.
b Number of rats with bladder stones/total. C P < 0.01. Significantly different from the nontreated group by the t test.
kept antibiotic free for 14 days. During and after treatment, urine for culture was collected by forced urination. Rats were killed 15 days after the final dose.
Rats infected with P. mirabilis and P. aeruginosa received E1040 or CAZ intramuscularly at 20 mg/kg. Amounts of unchanged E1040 and CAZ in the urine were determined by the thin-layer disc method, by using Escherichia coli E01174 as the test bacterium.
Urine and homogenized specimens of both kidneys were diluted with sterile physiological saline. The diluted solution was inoculated onto BTB and NAC agar medium (Eiken Co., Ltd.). On the other hand, bladder stones were removed from the bladder at autopsy. After being weighed, bladder stones were immersed in a 70% alcohol solution, washed twice with sterile physiological saline, and cultured as described by Nemoy and Stamey (4).
Blood specimens were collected from the aorta abdominalis for determination of blood urea nitrogen (BUN) by the method of Seligson and Seligson (8) .
The MICs and MBCs of E1040 were 0.2 and 0.8 ,ug/ml for P. mirabilis E05106 and 0.8 and 1.56 ,ug/ml for P. aeruginosa E030033, respectively. The MICs and MBCs of CAZ were 0.05 and 3.13 ,ug/ml for P. mirabilis and 0.1 and 3.13 ,ug/ml for P. aeruginosa, respectively.
In experiment 1 (the short-term regimen), both E1040 and CAZ markedly eradicated P. mirabilis from the urine and E1040 significantly eradicated P. aeruginosa from the urine, (Table 1) . Both E1040 and CAZ prevented development of infected bladder stones. In experiment 2 (the long-term regimen), both E1040 and CAZ markedly eradicated P. mirabilis from the urine, stonesi and kidneys (Table 2 ). E1040 significantly eradicated P. aeruginosa from the urine, in contrast to CAZ, reflecting its superior in vitro antipseudomonal activity. Both E1040 and CAZ significantly prevented stone development and kidney abscess formation compared with the nontreated group. The BUN values of animals treated with E1040 and CAZ stayed in the normal range. In experiment 3 (recurrence evaluation after the long-term regimen), recurrence of P. mirabilis infections was not observed in either E1040-or CAZ-treated animals. On the other hand, P. aeruginosa was markedly eradicated from the urine at the termination of the 14-day regimen of E1040, but recurrence of P. aeruginosa infection was noted in 5 of 10 cases at 14 days after discontinuation of the E1040 regimen. However, eradication of P. aeruginosa from the urine was insufficient at termination of the 14-day CAZ regimen, so that recurrence of P. aeruginosa infection was noted in six of nine cases (Fig. 1) . Development of infected stones was significantly prevented in both E1040-and CAZ-treated groups compared with the nontreated Values connected by brackets differ significantly (P < 0.01) by the x2 test.
CAZ stayed in the normal range (Table 3 ). Enterococcus faecalis infections were noted in the urine, stones, and kidneys of all of the rats tested. Our preliminary examination of this phenomenon indicated that E. faecalis infections were induced by transurethral cannulation of the rats with a polyethylene tube. The cumulative rates of urinary recovery of unchanged E1040 reached 47.3% of the total dosage (20 mg/kg) within 8 h, comparable to that of CAZ (47.2%), and a similar urinary excretion pattern was observed between E1040 and CAZ (Fig. 2) . The pharmacokinetic parameters of E1040 and CAZ after intravenous injection of infected rats were similar (Table 4) . It has been reported that E1040 was more effective than CAZ for systemic P. aeruginosa infections in mice (1, 13) . We evaluated the efficacies of E1040 and CAZ against Pseudomonas urinary tract infections, one of the representative local P. aeruginosa infections, by using our modified infection-induced bladder stone model in rats (7) . The short-term regimen (5 days) with E1040 or CAZ was insufficient to eradicate P. aeruginosa and P. mirabilis from the stones, compared with the corresponding long-term regimen (14 days). This indicates that the long-term regimen with antipseudomonal agents is required for effective management of Pseudomonas urinary tract infections associated with stones. E1040 was markedly superior to CAZ for eradication ofP. aeruginosa from the urine in both the shortand the long-term regimens. The pharmacokinetic parameters and urinary excretion pattern of E1040 were almost the same as those of CAZ in rats. Accordingly, the superior eradicative effect of E1040 might be attributable to its prominent antibacterial activity against P. aeruginosa. These findings suggest that E1040 is more promising than CAZ for management of acute aggravation of chronic complicated urinary tract infections, although recurrence of P. aerungnosa infection was noted 14 days after discontinuation of E1040 therapy. In terms of the relationship between the recurrence of urinary tract infections and the presence of (6) . Namely, the bioflim produced by bacteria makes it possible for residual bacteria to survive in urine with a high antibiotic concentration. Meanwhile, the judgement "not a positive culture" does not mean complete sterilization of a bacterium, owing to the detection limit of the present culture assay. In view of these findings, recurrence of P. aeruginosa infections in the present study may be attributable to the existence of a small number of residual P. aeruginosa organisms hiding in the biofilm on the surfaces and/or insides of bladder stones.
